MicroBase (3184) announced its 2024 financial results, reporting consolidated revenue of NT$214.76 million, up 10.28% YoY, with a 56% gross margin and record-high EPS of NT$0.86. Operating profit surged 147%, reflecting strong profitability and market competitiveness.
In recent years, MicroBase has actively optimized its operational structure, delivering remarkable results in 2023 with a net profit growth rate of 500%. This momentum continued in 2024, reflecting the effectiveness of the company’s strategic transformation. The sustained revenue growth was primarily driven by demand for inkjet printer nozzle plates in the electronic consumer product sector and an increasing revenue share and profitability in the medical device segment.
MicroBase stated that its management team has strengthened market positioning, optimized production processes, enhanced supply chain management, and implemented energy-saving policies to adapt to market dynamics. These efforts have contributed to a steady inflow of operating cash, reinforcing the company's financial stability and laying a solid foundation for future growth.
MicroBase continued investment in the medical field has yielded significant milestones. We announced a partnership between its Aerosol Drug Delivery Platform—GOCare® Portable Nebulizer—and Taiwan Biotech Co.,Ltd to expand medical distribution channels. Additionally, MicroBase has made strides in overseas market expansion, successfully obtaining a medical device license in Malaysia, further accelerating its international market presence.
As the global healthcare industry advances toward personalized medicine, MicroBase focuses on pediatric and elderly healthcare services while driving innovation in medical technology. The company has successfully developed high-viscosity drug nebulization modules and nanotechnology-based sustained-release nebulization technology. Moving forward, we will collaborate with global partners to develop customized combination product solutions, enhancing the quality of respiratory disease treatment and delivering more precise and efficient healthcare solutions worldwide.
